Doctor profile · Federal record
Dr. Leroy Adler, M.D.
Nuclear Medicine Physician (CMS: Diagnostic Radiology) · Jenkintown, PA
- NPI 1073518395
- Accepts Medicare
- 45 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
261 Old York RD Ste 106
Jenkintown, PA 190463726
(215) 935-0030
fax (215) 935-0023 - Mailing address
-
261 Old York RD, Ste 106
Jenkintown, PA 190463706
Credentials & registration
- NPI registered
- June 2005 — 21 yrs on file
- Profile last updated
- February 13, 2026
- Year of graduation
- 1981 — 45 yrs since
- Specialty taxonomy
- 207U00000X — NUCC code
- State license (1)
- Pennsylvania #MD029568E
- Medicaid
- PA #0018602680002
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1073518395. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
28
Distinct HCPCS
2
Medicare allowed
$18,457
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 17 | 16 | $119 | |
78608 |
Nuclear medicine study of brain with metabolic evaluation | 11 | 11 | $1,494 |
In context: peer comparison
Among 1 peers in this city , average services per provider: 14. This provider delivers 2.0× the peer median.Frequently asked questions
What is Dr. Leroy Adler's medical specialty?
Dr. Leroy Adler practices Nuclear Medicine Physician in Jenkintown, PA.
Where does Dr. Leroy Adler practice?
Dr. Leroy Adler practices at 261 Old York RD Ste 106, Jenkintown, PA 190463726. Office phone: 2159350030.
What is Dr. Leroy Adler's NPI?
Dr. Leroy Adler's National Provider Identifier (NPI) is 1073518395, issued by NPPES.
Does Dr. Leroy Adler accept Medicare assignment?
Yes. Dr. Leroy Adler accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Leroy Adler commonly perform?
Top Medicare-reported procedures in 2023: Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS A9552); Nuclear medicine study of brain with metabolic evaluation (HCPCS 78608). Source: CMS Medicare Physician & Other Practitioners file.